Laboratorieabnormiteter Laboratoriemæssige abnomiteter, som krævede behandling (grad 3 eller 4), som blev betragtet som bivirkninger, og som blev rapporteret hos ≥ 2% af patienterne i henholdsvis INTELENCE- gruppen og placebogruppen, var: forhøjelse af amylase (7, 5% over for 7, 9%), lipase (2, 7% over for 1, 7%), totalkolesterol (5, 8% over for 4, 1%), lavdensitetslipoprotein (LDL) (5, 2% over for 5, 4%), triglycerider (7, 0% over for 4, 3%), glukose (2, 5% over for 2, 0%), alaninaminotransferase (ALAT) (2, 5% over for 1, 7%), aspartataminotransferase (ASAT) (2, 5% over for 1, 7%) og reduktion i neutrofilocytter (3, 7% over for 6, 3%).
Laboratory abnormalities Treatment emergent clinical laboratory abnormalities (grade 3 or 4), considered ADRs, reported in ≥ 2% of patients in the INTELENCE arm versus the placebo arm, respectively, were increases in amylase (7.5% vs 7.9%), lipase (2.7% vs 1.7%), total cholesterol (5.8% vs 4.1%), low density lipoprotein (LDL) (5.2% vs 5.4%), triglycerides (7.0% vs 4.3%), glucose (2.5% vs 2.0%), alanine aminotransferase (ALT) (2.5% vs 1.7%), aspartate amino transferase (AST) (2.5% vs 1.7%) and decreases in neutrophils (3.7% vs 6.3%).